(Q39540986)

12 September 2017

1 reference

title

Gemfibrozil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidaemia (English)

1 reference

12 September 2017

0 references

1 reference

P A Todd

1

1 reference

12 September 2017

A Ward

series ordinal

2

1 reference

12 September 2017

1 September 1988

1 reference

12 September 2017

1 reference

12 September 2017

36

1 reference

12 September 2017

314-339

1 reference

12 September 2017

3

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-198836030-00004

12 September 2017

0 references

cites work

Pathogenesis and management of lipoprotein disorders

1 reference

12 December 2020

Effects of gemfibrozil on serum lipids

1 reference

12 December 2020

Determination of gemfibrozil in plasma by high performance liquid chromatography

1 reference

12 December 2020

Fat transport in lipoproteins--an integrated approach to mechanisms and disorders

1 reference

12 December 2020

The effect of gemfibrozil on serum lipids in diabetic patients

1 reference

12 December 2020

Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III, and type IV hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemfibrozil

1 reference

12 December 2020

Evaluation of selected hypolipidemic agents for the induction of peroxisomal enzymes and peroxisome proliferation in the rat liver.

1 reference

12 December 2020

Extrinsic factors affecting the response to gemfibrozil

1 reference

12 December 2020

Effect of gemfibrozil on serum lipids in man

1 reference

12 December 2020

Gallbladder Disease as a Side Effect of Drugs Influencing Lipid Metabolism Experience in the Coronary Drug Project

1 reference

12 December 2020

Letter: Clofibrate and gallstones

1 reference

12 December 2020

The effect of Gemfibrozil on human serum apolipoproteins and on serum reserve cholesterol binding capacity (SRCBC)

1 reference

12 December 2020

Effect of gemfibrozil on lipids, apoproteins, and postheparin lipolytic activities in normolipidemic subjects

1 reference

12 December 2020

Classification of hyperlipidaemias and hyperlipoproteinaemias

1 reference

12 December 2020

Gemfibrozil increases both apo A-I and apo E concentrations. Comparison to other lipid regulators in cholesterol-fed rats

1 reference

12 December 2020

A clofibrate controlled trial of gemfibrozil in the treatment of hyperlipidaemias

1 reference

12 December 2020

W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the Committee of Principal Investigators

1 reference

12 December 2020

Effect of gemfibrozil on lipoprotein concentrations in different types of hyperlipoproteinaemia

1 reference

12 December 2020

Gemfibrozil--a new lipid lowering agent

1 reference

12 December 2020

Effect of AY-25,712 and other lipid-lowering agents on liver catalase and liver carnitine acetyltransferase in rats

1 reference

12 December 2020

Quantitative microscopy comparison of peroxisome proliferation by the lipid-regulating agent gemfibrozil in several species

1 reference

12 December 2020

Light and electron microscopy of liver in hyperlipoproteinemic patients under long-term gemfibrozil treatment

1 reference

12 December 2020

Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis

1 reference

12 December 2020

Clofibrate therapy and gallstone induction

1 reference

12 December 2020

The effect of ICI 55,897 and clofibrate on platelet function and other tests abnormal in atherosclerosis

1 reference

12 December 2020

High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial

1 reference

12 December 2020

In vitro binding study of gemfibrozil to human serum proteins and erythrocytes: interactions with other drugs.

1 reference

12 December 2020

Effect of clofibrate and gemfibrozil on the activities of mitochondrial carnitine acyltransferases in rat liver dose-response relations

1 reference

12 December 2020

Gemfibrozil in combination with other drugs for severe hyperlipidemia. Preliminary study comprising four cases

1 reference

12 December 2020

Serum lipoprotein lipids after gemfibrozil treatment

1 reference

12 December 2020

Summary of present data from a clinical trial of CI-719

1 reference

12 December 2020

The treatment of hyperlipoproteinaemia with gemfibrozil compared with placebo and clofibrate

1 reference

12 December 2020

Plasma Prekallikrein, Kallikrein Inhibitors, Kininogen and Lipids during Gemfibrozil Treatment in Type II Dyslipidaemia

1 reference

12 December 2020

1 reference

12 December 2020

Gemfibrozil therapy in primary hypertriglyceridemia associated with coronary heart disease. Effects on metabolism of low-density lipoproteins

1 reference

12 December 2020

Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia

1 reference

12 December 2020

The Gemfibrozil Study

1 reference

12 December 2020

Apolipoprotein changes associated with the plasma lipid-regulating activity of gemfibrozil in cholesterol-fed rats

1 reference

12 December 2020

Toleration and bioavailability of gemfibrozil in healthy men.

1 reference

12 December 2020

Gemfibrozil--the effect of biliary cholesterol saturation of a new lipid-lowering agent and its comparison with clofibrate.

1 reference

12 December 2020

CI-719 in hyperlipoproteinaemia: interim data

1 reference

12 December 2020

Association of hyperapobetalipoproteinemia with endogenous hypertriglyceridemia and atherosclerosis

1 reference

12 December 2020

The effect of gemfibrocil on serum lipids and lipoproteins in patients with hyperlipoproteinemia

1 reference

12 December 2020

Mechanisms of action of clofibrate on cholesterol metabolism in patients with hyperlipidemia

1 reference

12 December 2020

Gemfibrozil Treatment: A Comparison with Clofibrate

1 reference

12 December 2020

The rapid induction of liver glycerophosphate acyltransferase in mice by clofibrate, a hypolipidemic agent

1 reference

12 December 2020

Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study.

1 reference

12 December 2020

Apolipoprotein A-I as a marker of angiographically assessed coronary-artery disease

1 reference

12 December 2020

A long-term trial of gemfibrozil in the treatment of hyperlipidaemias

1 reference

12 December 2020

Plasma triglycerides related decrease in high-density lipoprotein cholesterol and its association with myocardial infarction in heterozygous familial hypercholesterolemia.

1 reference

12 December 2020

Effect of gemfibrozil in vitro on fat-mobilizing lipolysis in human adipose tissue

1 reference

12 December 2020

Change in composition of high density lipoprotein during gemfibrozil therapy

1 reference

12 December 2020

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

12 December 2020

Influence of Gemfibrozil and Clofibrate on Metabolism of Cholesterol and Plasma Triglycerides in Man

1 reference

12 December 2020

Toxicological studies on gemfibrozil

1 reference

12 December 2020

Some comparative effects of gemfibrozil, clofibrate, bezafibrate, cholestyramine and compactin on sterol metabolism in rats

1 reference

12 December 2020

A comparison of different formulations and dosage administrations of gemfibrozil

1 reference

12 December 2020

The effect of CI-719 on lipolysis in rat adipose tissue

1 reference

12 December 2020

Preliminary observations on the effect of gemfibrozil on the excretion of faecal bile acids

1 reference

12 December 2020

Long-term use of gemfibrozil (Lopid) in the treatment of dyslipidemia

1 reference

12 December 2020

Transport kinetics of plasma free fatty acid, very low density lipoprotein triglycerides and apoprotein in patients with endogenous hypertriglyceridaemia Effect of 2,2-dimethyl, 5(2,5-xylyloxy) valeric acid therapy

1 reference

12 December 2020

The Tromsø heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study

1 reference

12 December 2020

Association of coronary atherosclerosis with hyperapobetalipoproteinemia [increased protein but normal cholesterol levels in human plasma low density (beta) lipoproteins]

1 reference

12 December 2020

Apoproteins B and A-I and coronary artery disease in humans.

1 reference

12 December 2020

Prevalence of gallstones in hyperlipidemia and incidence during treatment with clofibrate and/or cholestyramine

1 reference

12 December 2020

Carcinogen bioassay and mutagenicity studies with the hypolipidemic agent gemfibrozil.

1 reference

12 December 2020

Clinical results with gemfibrozil and background to the Helsinki Heart Study

1 reference

12 December 2020

Hypolipidemics Carcinogenicity and Extrapolation of Experimental Results for Human Safety Assessments

1 reference

12 December 2020

The effect of renal function on the pharmacokinetics of gemfibrozil

1 reference

12 December 2020

Gemfibrozil in the treatment of dyslipidaemias in middle-aged male survivors of myocardial infarction

1 reference

12 December 2020

The use of gemfibrozil in the treatment of primary hyperlipoproteinaemia. Preliminary report

1 reference

12 December 2020

The metabolism of gemfibrozil

1 reference

12 December 2020

Effects of gemfibrozil on plasma lipoprotein-apolipoprotein distribution and platelet reactivity in patients with hypertriglyceridemia.

1 reference

12 December 2020

Effect of gemfibrozil upon platelet function and blood coagulation. Preliminary report

1 reference

12 December 2020

The hypolipidaemic effect of gemfibrozil (CI-719) in laboratory animals

1 reference

12 December 2020

Lipokinetic studies with gemfibrozil (CI-719)

1 reference

12 December 2020

Evaluation of increasing doses of gemfibrozil in hyperlipoproteinaemia

1 reference

12 December 2020

Hyperlipoproteinemia, atherosclerosis and gemfibrozil

1 reference

12 December 2020

Effect of gemfibrozil on biliary lipid metabolism in normolipemic subjects

1 reference

12 December 2020

Gemfibrozil in the treatment of dyslipidaemia. A 5-year follow-up study

1 reference

12 December 2020

Gas chromatographic determination of gemfibrozil and its metabolites in plasma and urine

1 reference

12 December 2020

Gemfibrozil and clofibrate in the treatment of hyperlipidaemias. A comparative trial

1 reference

12 December 2020

Gemfibrozil in a group of diabetics

1 reference

12 December 2020

10.2165/00003495-198836030-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

12 September 2017

1051255394

0 references

Fatcat ID

release_nufriilwhbagdhebrr65edpnam

0 references

1 reference